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infection)Most pharmaceutical companies have stopped or have severely limited investments to discover and
develop new antibiotics to treat the increasing prevalence of infections caused by multi-drug resistant
bacteria, because the return on investment has been mostly negative for antibiotics that received market-
ing approved in the last few decades. In contrast, a few small companies have taken on this challenge and
are developing new antibiotics. This review describes those antibiotics in late-stage clinical development.
Most of them belong to existing antibiotic classes and a few with a narrow spectrum of activity are novel
compounds directed against novel targets. The reasons for some of the past failures to find newmolecules
and a path forward to help attract investments to fund discovery of new antibiotics are described.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
2. Why is it difficult to obtain investments for new antibiotics? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
3. Antibiotics that have been approved in recent years. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
4. Beta-lactamases, cephalosporinase, and carbapenemase inhibitors in combination with old and new beta-lactams. . . . . . . . . . . . . . . . . . . . . . . 00
5. New cephalosporins and beta-lactams that have activity against beta-lactamase and carbapenemase-producing bacteria . . . . . . . . . . . . . . . . . 00
6. New aminoglycosides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
7. New pleuromutilins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
8. New tetracyclines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
9. New macrolides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
10. New fluoroquinolones and DNA gyrase inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
11. New oxazolidinones. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
12. New fatty acid biosynthesis inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
13. New folate biosynthesis inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
14. Defensin-mimetic peptides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
15. Other classes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
16. Old antibiotics with new dosing regimens. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0016.1. Ramoplanin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
16.2. Fusidane. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
16.3. Fosfomycin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0017. Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
18. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
Funding. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 000.1016/
2 P. Fernandes, E. Martens / Biochemical Pharmacology xxx (2016) xxx–xxx
P
jConflict of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 001. Introduction
Antibiotics are the first successful class of drugs that can cure
disease and have been effective in treating many infections. Most
of the antibiotics that are commonly used today were discovered
in what is known as the ‘‘Golden Age” of antibiotics [1], have lost
patent protection, and as with most generic drugs, are low priced.
Low cost and easy access have led to their overuse and misuse.
Bacteria evolve when subjected to selective pressure and multi-
antibiotic resistance in organisms as ubiquitous as Escherichia coli
and Staphylococcus aureus has been observed. Antibiotic resistance
has drawn attention from infectious diseases specialists, the Cen-
ters for Disease Control and Prevention, the World Health Organi-
zation, and U.S. and European governments [2–4]. Large
pharmaceutical companies have re-directed their resources to
develop drugs for chronic use, and for other areas, such as cancer,
where the drugs can be priced high, leaving antibiotic discovery
and development to small companies and start-up biotechnology
companies.2. Why is it difficult to obtain investments for new antibiotics?
Many companies have been founded based on early-stage mole-
cules or on screening methods against new targets. Novel com-
pounds directed against novel targets have been reported against
specific pathogens [5]. Pharmaceutical companies have invested
in such programs over the past few decades but were not success-
ful in finding new products. Some reasons for the lack of success of
these programs are described here: i) Simple, small molecules
directed against enzyme targets selected for resistance rapidly,
even during treatment [1,5]. It should be noted that previous
antibiotics were generally complex natural products with multiple
binding sites at the target, making it less likely for resistance selec-
tion. ii) Many novel targets are genus, species or even strain spe-
cific. Clinical trials for new antibiotics are expected to cover
disease indications that could have more than one bacterial species
involved in the infection and not just a single pathogen. Recently
approved, highly effective antibiotics, such as fidaxomicin that is
pathogen-specific for Clostridium difficile, has not been able to com-
pete in the market with older generics, such as vancomycin, which
has uses in infections caused by other Gram-positive bacteria and
therefore broader commercial use (such drugs are generally effec-
tive and sold at a lower price). iii) Antibiotic dosages are often in
the range of hundreds of milligrams per day, so they should have
exquisite selectivity for bacteria to avoid toxic effects on mam-
malian cells. However, many molecules that are active against bac-
teria are not selective and can cause collateral damage in the host.
Exceptions are certain antibiotics, such as the polymyxins that
have unacceptable renal toxicities that are used as the last resort
to treat infections caused by multi-drug resistant pathogens. Rapid,
ideally bedside, diagnostic tools using modern technology would
be helpful to select a narrow spectrum, targeted therapy. Although
a few have been approved for clinical use, the cost of these tools
has impeded wide use. As a consequence of the above, new antibi-
otics are frequently reserved as a last resort for infections caused
by multi-drug resistant pathogens that have failed treatment with
currently available antibiotics. For all the reasons described above,
investments made by large pharmaceutical companies did not leadlease cite this article in press as: P. Fernandes, E. Martens, Antibiotics in late cli
.bcp.2016.09.025to profitable products and the majority of pharmaceutical compa-
nies have exited this therapeutic area.
If large pharmaceutical companies have failed, why do startup
companies believe they can find new antibiotics? Small start-up
companies believe they can succeed where large companies do
not because they take novel approaches to drug development,
and have smaller commercialization needs to cover infrastructure
costs. For example, novel natural product screening methods are
being tested [6]; total synthesis of tetracyclines and macrolides
which are of natural product origin have been conducted to allow
modifications in the structure, that were hitherto not accessible to
semi-synthesis [7,8]; novel chemistries [8]; expression of polyke-
tide genes in heterologous hosts to synthesize new, complex prod-
ucts [9,10]. In addition, start-up companies have a razor-sharp
focus and persistence to overcome barriers to development such
as in chemistry or bioavailability. These approaches are expected
to be helpful in finding new molecules for the drug discovery
and development in start-up small companies that have the advan-
tage of a singular focus with lower cost programs.
3. Antibiotics that have been approved in recent years
Three antibiotics, telithromycin, temafloxacin and trovofloxacin
that were approved in the late 1990s and in the early 2000s were
reported to have serious adverse events and subsequent product
discontinuations [11–13]. These product failures and broad use of
antibiotics, especially for simple infections, which amplified less
frequent adverse events led to major changes in U.S. Food and Drug
Administration (FDA) and European Medicines Agency (EMA) guid-
ance documents for conducting clinical trials. Efficacy endpoints
were set with greater definition and clinical trials using non-
inferiority margins were for complicated infections only. Steward-
ship and the movement to limit antibiotic usage are at odds with
antibiotic use in simple infections, such as sinusitis and otitis
media. The FDA guidance for clinical trials in simple infections
requires that superiority be demonstrated [14]. Such trials are dif-
ficult to enroll and would need to be extraordinarily large to
achieve statistical superiority, since most of these infections can
resolve without therapy. Thus, new antibiotic approval is generally
limited to marketing for complicated or more serious infections.
Once approved, stewardship is likely to be practiced because of
limited label indications and higher cost. According to the Associ-
ation for Professionals in Infection Control and Epidemiology
(APIC), antibiotic stewardship ‘‘promotes the appropriate use of
antibiotics, improves patient outcomes, reduces microbial resis-
tance, and decreases the spread of infections caused by
multidrug-resistant organisms” [15]. The Infectious Diseases Soci-
ety of America (IDSA) further emphasizes that selecting the opti-
mal drug regimen, dose, duration, and route of administration
are critical to the practice of stewardship. Furthermore, steward-
ship seeks to minimize toxicity and other adverse events as well
as reduce the costs of healthcare infections [16].
During the last 6 years the following small molecule antibiotics
have received marketing authorization: ceftaroline for acute bacte-
rial skin and skin structure infection (ABSSSI) and community-
acquired bacterial pneumonia (CABP); oritavancin for ABSSSI and
CABP; telavancin for ABSSSI and CABP; dalbavancin for ABSSSI;
tedizolid for ABSSSI; fidaxomicin for C. difficile colitis;
ceftazidime-avibactam for complicated urinary tract infectionnical development, Biochem. Pharmacol. (2016), http://dx.doi.org/10.1016/
Sales of Recently Launched 
Antibiotics ($M)
Avycaz
Teflaro
Sivextro
Zerbaxa
Dalvance
Orbactiv
50 100–
Millions
Year 1 Year 2
(a)
Sales of Other Products ($M)
Teflaro
Linzess
Symbicort
Xarelto
Eliquis
Xifaxin
Vyvanse
Spiriva
Lyrica
Januvia
500 1,5001,000–
Millions
Year 1 Year 2
(b)
Fig. 1. (a and b) Product launches: new antibiotics vs. other brands: disappointing sales of recently launched antibiotics (20 M–80 M) two years post launch; Teflaro
(ceftaroline fosamil), an IV antibiotic indicated for CABP had sales $50 M 2 years post launch, while other classes of drugs had sales between $500 million – over $1B.
*Projected Sales (year 2). Source: NSP $ Sales, IMS 2016.
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avibactam for IAI and cUTI. Although the regulatory path is now
clear, the revenues generated from each of these products is still
small and the return on investment is low or negative compared
with those of other therapeutic areas. (Fig. 1a, b). It is important
to note that dalbavancin, telavancin and oritavancin compete with
generic vancomycin and daptomycin. These new antibiotics were
approved based on non-inferiority to lower cost antibiotics, and
although the newer antibiotics may offer a more convenient dosing
schedule, this alone has not convinced payers and patients that
new antibiotics offer higher value. Fidaxomicin, as noted previ-
ously, must compete with generic vancomycin and metronidazole.
Ceftaroline must compete with generic ceftriaxone, and tedizolid
must compete with generic linezolid. Except for tedizolid, all
recently approved antibiotics are administered intravenously. Gen-
eric antibiotics continue to be used in the outpatient sector despite
treatment failures and increased hospitalizations [17].
This review will discuss those small molecules that are in late
clinical development, i.e., those in Phase 3 clinical trials or with
published Phase 2 clinical trial data. Where possible, antibiotics
under development are grouped by class and similar mechanism
of action. This review will focus on small molecules only and not
vaccines, phage or antibody therapies.4. Beta-lactamases, cephalosporinase, and carbapenemase
inhibitors in combination with old and new beta-lactams
The success of ampicillin-clavulanic acid and ampicillin-
sulbactam combinations that were widely used in outpatients,
especially for urinary tract infections has led to the selection of
new beta-lactamases and more treatment failures. Piperacillin-
tazobactam, a next-generation product, was developed in the
1990s to treat serious Gram-negative infections, such as intra-
abdominal infections and complicated urinary tract infections.
The increasing incidence of new cephalosporinase and carbapene-
mases since introduction of piperacillin-tazobactam increased the
interest in finding new beta-lactam plus new beta-lactamase inhi-
bitor combinations [18,19]. Ceftazidime-avibactam (Avycaz) (1), a
fixed-combination drug containing ceftazidime, a generic third-
generation cephalosporin, and avibactam, a new beta-lactamase
inhibitor, received regulatory approval to treat adults with compli-
cated intra-abdominal infections (cIAI), and complicated urinaryPlease cite this article in press as: P. Fernandes, E. Martens, Antibiotics in late cli
j.bcp.2016.09.025tract infections (cUTI) who have limited or no alternative treat-
ment options. Interestingly, this approval was supported, in part,
by the efficacy and safety of ceftazidime for the treatment of cIAI
and cUTI. The contribution of avibactam to Avycaz was based on
data from in vitro studies and animal models of infection. Two
Phase 3 trials for Avycaz, one each in cIAI and cUTI were conducted
(NCT01726023, NCT01599806) (Fig. 2).
Another cephalosporin–beta-lactamase inhibitor combination
that was recently approved (December 2014) by the U.S. FDA was
ceftolozane/tazobactam (Zerbaxa) (2), also used to treat adults with
cIAI and cUTI. In this combination, the cephalosporin is new and the
beta-lactam inhibitor was known, being the same beta-lactamase
inhibitor as in piperacillin-tazobactam. Like the efficacy of the
ceftazidime-avibactam combination, ceftolozane/tazobactam’s effi-
cacy to treat cIAI in combination with metronidazole was estab-
lished in a clinical trial (NCT01147640) with a total of 979 adults.
The results showed that Zerbaxa plus metronidazole was effective
for the treatment of cIAI. In addition, the efficacy of Zerbaxa to treat
cUTI was established in a clinical trial of 1068 patients where it was
shown to be non-inferior to levofloxacin (NCT01345929).
Klebsiella pneumoniae strains resistant to carbapenem
(carbapenem-resistant Enterobacteriaceae or CRE), have been
reported. Effort is underway to find new combinations to treat
these infections. Carbavance (Rempex, a subsidiary of Medicines
Company), is a meropenem and a novel boronic beta-lactamase
inhibitor RPX7009 (3) (aka vaborbactam) [20]. It is in Phase 3
development and will target Gram-negative bacteria that produce
new beta-lactamase enzymes that have spread in the U.S. and
Europe, including strains producing the Klebsiella pneumoniae car-
bapenemase (KPC) enzyme. The first Phase 3 trial (TANGO 1)
(NCT02166476) was a randomized, comparative study against
piperacillin/tazobactam for the treatment of cUTI. Carbavance
was statistically superior to piperacillin/tazobactam, with overall
success in 98.4% of treated patients. Safety of carbavance was com-
parable to that of piperacillin/tazobactam. A second Phase 3 trial
(TANGO 2) (NCT02168946) is a multi-center, randomized, open-
label study of carbavance versus best available therapy in subjects
with selected serious infections due to CRE. Approximately 150
study subjects with cUTI, nosocomial pneumonia and/or bac-
teremia are expected to be randomly assigned (2:1) to carbavance
or ‘‘best available therapy” for up to 14 days. This study is ongoing
and will provide supportive data for the regulatory marketing
authorization submission. When approved, carbavance will targetnical development, Biochem. Pharmacol. (2016), http://dx.doi.org/10.1016/
Fig. 2. Structures of compounds targeting new beta-lactamase producing enteric pathogens: i) beta-lactamases: Beta-lactam–beta-lactamase inhibitors. Only the chemical
structures of new members of each combination are shown: 1) Avibactam; 2) Ceftolozane; 3) Vaborbactam (RPX7009); 4) Relebactam; ii) Siderophore-containing beta
lactams: 5) S649266.
4 P. Fernandes, E. Martens / Biochemical Pharmacology xxx (2016) xxx–xxxthe urgent and growing global threat of deadly Gram-negative ‘‘su-
perbugs”, including the CRE.
In an effort to meet the growing need for antibiotics to treat
CRE, a new monobactam antibiotic, relebactam (4), in combination
with the old carbapenem, imipenem, and the carbapenemase inhi-
bitor, cilastatin (MK-7655) is being developed (Merck & Co. Inc.)
[21]. The challenge is to optimize the pharmacokinetics and safety
for three drugs while gaining efficacy against CRE and other serious
infections caused by Gram-negative bacteria. The target indica-
tions are cUTI, acute pyelonephritis, cIAI, and hospital-acquired
bacterial pneumonia (HAP)/ventilator-associated bacterial pneu-
monia (VAP). In a phase 2 blinded, comparative study of patients
with cUTI or acute pyelonephritis (NCT01505634), relebactam plus
imipenem/cilastatin was non-inferior to imipenem/cilastatin alone
in the proportion of microbiologically evaluable patients with a
favorable microbiological outcome at the end of IV infusion. A
phase 3 trial of relebactam with imipenem/cilastatin has been
initiated in which imipenem/cilastatin/relebactam is being com-
pared to colistin in combination with imipenem/cilastatin for
the treatment of resistant bacterial infections, including those
caused by Pseudomonas aeruginosa and KPC-producing organisms
(NCT02452047). A second phase 3 study is also enrolling patients,
in which a fixed-dose combination of imipenem/relebactam/cilasta
tin is being compared to piperacillin/tazobactam in patients with
HAP/VAP (NCT02493764).
Another combination, avibactam with aztreonam (AstraZeneca
plc. and its U.S. partner Allergan plc., formerly Actavis), another
generic antibiotic, is being developed for the treatment of IAI along
with metallo-b-lactamase-producing Gram-negative infections
[22]. It is currently in Phase 2 clinical development but with thePlease cite this article in press as: P. Fernandes, E. Martens, Antibiotics in late cli
j.bcp.2016.09.025precedence of avibactam and aztreonam both being approved
drugs, the combinations may receive regulatory approval without
additional trials. (A phase 2 trial to determine the PK, safety, and
tolerability of aztreonam-avibactam (ATM-AVI) in the treatment
of hospitalized patients with cIAI is currently recruiting patients;
NCT02655419). This could be similar to an ‘‘Intel inside” model,
where avibactam could be used in combination with other peni-
cillins, monobactams, cephems and cephalosporins giving new life
to old beta-lactams.
Other beta-lactamase inhibitors are in development but no
other combinations are in late clinical development capable of
addressing new beta-lactamases that are likely to evolve but enter-
ing a crowded antibiotic market.5. New cephalosporins and beta-lactams that have activity
against beta-lactamase and carbapenemase-producing bacteria
A new cephalosporin, which is not being used in combination
with a beta-lactamase inhibitor but does have activity against
beta-lactamase and carbapenemase-producing pathogens, is S-
649266 [23]. S649266 (Shionogi Inc.) is a novel, siderophore
cephalosporin (5). It is an injectable cephalosporin in Phase 3 devel-
opment, which is highly active against Gram-negative pathogens
including multidrug-resistant Gram-negative bacteria known to
cause bloodstream infections, HAP, VAP, and cUTI. It was shown to
be effective in a Phase 2 trial in cUTI (NCT02321800) and is currently
being evaluated in a Phase 3 study (CREDIBLE) for treatment of
severe infections caused by carbapenem-resistant Gram-negative
pathogens (NCT02714595).nical development, Biochem. Pharmacol. (2016), http://dx.doi.org/10.1016/
P. Fernandes, E. Martens / Biochemical Pharmacology xxx (2016) xxx–xxx 5Although BAL30072 [24] (Basilea Pharmaceutica Ltd.) is in ear-
lier clinical development, it is mentioned here as it is a new side-
rophore monosulfactam antibiotic (6) with activity against
multidrug-resistant Gram-negative bacteria. It also utilizes natural
iron uptake systems to gain access to its target. The siderophore
side chain also contributes directly to its antibacterial activity
against clinically increasingly problematic multidrug-resistant
Gram-negative bacteria such as Pseudomonas spp. and Klebsiella
spp. Furthermore, there is new evidence that an accelerated uptake
of BAL30072, facilitated by the compound’s siderophore side chain,
potentiates its in vitro activity against Acinetobacter baumannii, a
pathogen that can cause severe pneumonia, infections of the uri-
nary tract, and bacteremia.6. New aminoglycosides
Streptomycin was the first aminoglycoside discovered in 1943
and is known for being one of the early drugs used to treat tuber-
culosis. Gentamicin, also a natural product is an aminoglycoside
that was introduced in the 1960s to treat P. aeruginosa infections.
This was followed by newer aminoglycosides, the most successful
being tobramycin and in the 1980s, amikacin. Resistance to the
older aminoglycosides, such as gentamicin and tobramycin is
now widespread. There are three main mechanisms of aminogly-
coside resistance that are known: decreased cell permeability;
alterations at the ribosomal binding sites; and production of
aminoglycoside modifying enzymes. Permeability mutants have
low-level resistance. While resistance caused by ribosomal muta-
tions that interfere with binding to the 30S subunit is rare and
occurs primarily with streptomycin, the newer aminoglycosides
have multiple binding sites and therefore resistance cannot be
selected by a single step mutation. There are over 50 different bac-
terial antibiotic resistance-modifying enzymes, with some isolates
carrying more than one enzyme, making this the most common
type of aminoglycoside resistance. Enzymatic modification results
in high-level resistance. There are three types of aminoglycoside
modifying enzymes: N-Acetyltransferases, O-Adenyltransferases
and O-Phosphotransferases. Amikacin is currently the most potent
aminoglycoside, but resistance to this drug has been observed.
Aminoglycosides were introduced as intravenous therapies for
serious Gram-negative infections but their use is secondary to
the cephalosporins and carbapenems due to the need to monitor
aminoglycoside blood concentration to avoid aminoglycoside-
associated ototoxicity and nephrotoxicity. Newer aminoglycosides
share the same narrow therapeutic window with the older amino-
glycosides. More recently, the site of interaction that results in oto-
toxicity has been characterized [25] and may provide a tool for
screening these compounds in the future.
Plazomicin (7) (Achaogen, Inc.) is a new aminoglycoside that is
in Phase 3 development for the treatment of serious bacterial
infections due to MDR Enterobacteriaceae, including CRE [26].
Two Phase 3 trials are currently underway. The first trial (EPIC),
with a planned enrollment of 530 patients, is a pivotal marketing
registrational study to evaluate plazomicin treatment of cUTI,
including acute pyelonephritis (NCT02486627). The second trial
(CARE), with a planned enrollment of 100 patients, is a supportive
study to evaluate plazomicin treatment of serious CRE infections
(NCT01970371).7. New pleuromutilins
Pleuromutilin is a natural product of the fungi Pleurotus mutilus
(now called Clitopilus scyphoides) that inhibits bacterial protein
synthesis by binding to the peptidyl transferase site on 23S RNA
of the 50S ribosome. Many analogs have been made to enhancePlease cite this article in press as: P. Fernandes, E. Martens, Antibiotics in late cli
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sively. The structure consists of a common tricyclic mutilin core,
a C21 keto group, essential for antimicrobial activity, and various
diverse chemical extensions at C14. During the early 1980s, exten-
sive effort was devoted to formulate azamulin [27] but because of
potent inhibition of cytochrome P450, its development was subse-
quently discontinued. Another member of this class, retapamulin,
was approved by the FDA in 2006 for topical use to treat impetigo.
Another pleuoromutilin, tiamulin, has been used as a veterinary
drug in Europe and Canada.
Lefamulin (BC-3781) (8) (Nabriva Therapeutics AG), which was
discovered at Roche, is a semi-synthetic compound that inhibits
bacterial protein synthesis [28,29]. However, during a brief period
of out-license in the US to Forest laboratories, it was tested in a
Phase 2 trial for ABSSSI against vancomycin (NCT01119105). Lefa-
mulin has a spectrum of activity that includes multi-drug resistant
Gram-positive strains. In the completed Phase 2 trial in ABSSSI that
was conducted by Forest Laboratories (NCT01119105), intravenous
lefamulin achieved a high cure rate against multi-drug resistant
Gram-positive bacteria, including methicillin-resistant Staphylo-
coccus aureus (MRSA). It also achieves high drug concentrations
in the lung tissue and is expected to be available in both IV and oral
formulations. A Phase 3 trial in CABP using intravenous and oral
lefamulin (NCT02559310) was initiated in September 2015 and a
second Phase 3 trial in CABP (NCT02813694) using oral lefamulin
was initiated in April 2016. If these trials are successful and lefa-
mulin is approved, it would be the first pleuromutilin antibiotic
available for systemic human infections.8. New tetracyclines
The tetracyclines are another old class of natural product antibi-
otics, discovered in the 1940s. Initially, theywere used topically but
after the development of doxycycline, they were used to treat a
variety of infections including respiratory tract and skin infections.
Tetracyclines also inhibit protein synthesis by inhibiting acyl-tRNA
transfer on the 30S ribosome. Tetracyclines have a fused linear
tetracyclic structure and form chelation complexes with divalent
cations. Analogs that reduce chelation also have lower activity.
Tetracyclines have broad-spectrum activity, including against
Gram-positive and Gram-negative bacteria as well as anaerobic
bacteria. Their use has been limited to adults because of their cal-
cium complexing properties, but even in adults, their use has been
limited by gastrointestinal side effects, especially nausea. They are a
useful antibiotic class for patients who are intolerant of macrolides
and for treating infections due to macrolide-resistant pathogens.
Resistance to tetracyclines results from small proteins that block
the tetracycline-binding site on the ribosome or by the expression
of efflux proteins [30]. Tigecycline is a semi-synthetic tetracycline,
called a glycylcycline, that is administered intravenously for treat-
ing serious infections caused by resistant S. aureus, A. baumannii,
and E. coli. The major side effects are nausea, vomiting, and diar-
rhea. There is also a small but significant (0.6%, with a correspond-
ing 95% confidence interval (0.0%, 1.2%) unexplained increase in
mortality that resulted in an FDA required black box warning.
Omadacycline (9) (Paratek Pharmaceuticals Inc.) was developed
with the goal of finding potent tetracycline molecules with activity
against resistant pathogens and that could be administered
intravenously and orally. It is semi-synthetically derived from
tetracycline in a subclass called the aminomethylcyclines. It has a
broad-spectrum of activity, for Gram-positive, Gram-negative,
aerobes, anaerobes, and atypical bacteria. It is being developed for
the treatment of ABSSSI and CABP, and is expected to be available
in intravenous and oral formulations for use in the hospital and out-
patient settings [31]. In the first Phase 3 trial (NCT02378480), anical development, Biochem. Pharmacol. (2016), http://dx.doi.org/10.1016/
Fig. 3. Chemical structures of the following molecules are shown: 6) BAL30072; 7) Plazomicin; 8) Lefamulin; 9) Omadacycline; 10) Eravacycline.
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treatment of ABSSSI (OASIS), the primary and secondary endpoints
were achieved for both oral and IV omadacycline. A second Phase 3
trial comparing omadacycline to moxifloxacin for CABP is currently
enrolling (NCT02531438) (Fig. 3).
Natural products are complex molecules. Semi-synthetic ana-
logs can be made but access using synthetic chemistry to some
of the sites on the core molecule is limited. Myers et al. [7,8] were
able to synthesize tetracyclines synthetically and this led to further
exploration of the structure to make analogs. One analog that was
derived from this new chemistry is eravacycline (Tetraphase Phar-
maceuticals) (10), a broad-spectrum, potent tetracycline against
multidrug-resistant (MDR) Gram-negative bacteria, being devel-
oped for treatment of IAI and cUTI [32]. In the first Phase 3 trial
(NCT01844856), a comparative study in cIAI (IGNITE1), eravacy-
cline met the primary endpoint of non-inferiority of the clinical
response rate. In the second Phase 3 trial (NCT01978938), a study
of intravenous to oral eravacycline compared to levofloxacin inPlease cite this article in press as: P. Fernandes, E. Martens, Antibiotics in late cli
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Eravacycline’s path to regulatory approval is likely through a sec-
ond IAI trial but its commercial potential has been decreased with
the failure of the oral formulation.
9. New macrolides
Erythromycin was the first member of the macrolide class that
was developed for clinical use in the 1950s. In the 1980s, two
acid-stable analogs, clarithromycin and azithromycin, were devel-
oped. Macrolides are frequently used for respiratory tract infections
as they have targeted activity against respiratory pathogens.
Macrolide antibiotics achieve high tissue and intracellular concen-
trations, which helps to address bacteria that are intracellular. In
addition, they have strong anti-inflammatory properties. Macro-
lides inhibit protein synthesis by binding to the 23S RNA of the
50S ribosomal subunit at the exit of the peptide synthesis tunnel.
Resistance to the approvedmacrolides is caused bymethylases thatnical development, Biochem. Pharmacol. (2016), http://dx.doi.org/10.1016/
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level resistance is a result of expression of efflux proteins and both
methylases and efflux proteins can be expressed in the same strain.
In 2001, a new macrolide, telithromycin, belonging to a new sub-
class called ketolide, received marketing approval. Ketolides are
macrolides in which a keto group replaces the cladinose sugar in
the older macrolides. In addition, there is an alkyl-aryl side chain
at the 11–12 position. The side chain allows telithromycin to inter-
act at additional sites on the 23S RNA of the bacterial ribosome and
this confers activity against strains that are resistant to the older
macrolides [33,34]. Following telithromycin’s approval in the US
in 2003, a series of serious adverse events that included hepatotox-
icity, visual disturbance, syncope and exacerbation of myasthenia
gravis were reported, which led to changes in the labeled indica-
tion. Although still approved for the treatment of CABP, it is no
longer used because of the serious adverse events. Cethromycin,
another ketolide, was developed for respiratory tract infections
but not approved based on lack of efficacy. Solithromycin is a fluo-
roketolide, with a fluorine at the 2-position of the macrolactone
ring (11) and an alkyl-aryl side chain at the 11–12 position of the
macrolactone ring. It is the next generation macrolide/ketolide as
it has activity against telithromycin-resistant bacteria [34]. Work-
ing with experts in the nicotinic acetylcholine receptor area, Cem-
pra Inc., conducted extensive work to show that the pyridine on
the side chain of telithromycin inhibits the nACh receptors in the
eye, neuromuscular junction, liver and brain. Inhibition of these
receptors is known to cause the same effects as was observed with
telithromycin. Having determined the reasons for the adverse
events of telithromycin, Cempra was able to continue the develop-
ment of solithromycin. Cempra has completed two Phase 3 trials
(Solitaire trials) in CABP where solithromycin was shown to be
non-inferior to the comparator fluoroquinolone, moxifloxacin. The
first Phase 3 trial (NCT01756339) tested oral capsules of solithro-
mycin while the second Phase 3 trial (NCT01968733) tested the
intravenous formulation, allowing a switch to the oral capsules of
solithromycin. The results of these two trials have been published
[35,36]. Solithromycin has good oral bioavailability, is stable in
solution, does not prolong cardiac QT interval, and has demon-
strated activity against azithromycin-resistant and telithromycin-
resistant strains both in vivo and in vitro. New drug applications
have been submitted to the FDA and an MAA has been submitted
in the European Union. Toyama/Fujifilm, who have licensed soli-
thromycin for use in Japan, have completed a successful Phase 2
trial in CABP where solithromycin was comparable to levofloxacin.
Marketing authorization in the US is expected at the end of 2016.
Following successful treatment of urogenital gonorrhea in a com-
parative Phase 2 trial (NCT01591447) [37], solithromycin is now
being tested in a Phase 3 trial (NCT02210325). Solithromycin is also
being tested in pediatrics and a Phase 2/3 pivotal trial
(NCT02605122) in pediatric patients (2 months to 17 years of age)
with CABP has been initiated. In addition to the oral capsules and
intravenous formulation, a suspension formulation has been devel-
oped to provide dosing flexibility for treating children. Finally,
non-clinical studies have demonstrated the potential utility of
solithromycin for the treatment of infections in pregnancy [38].10. New fluoroquinolones and DNA gyrase inhibitors
Nalidixic acid was the first quinolone antibacterial agent, which
although not of microbial origin also originated indirectly from a
natural product, the by-product of chloroquine synthesis, which
itself is an analog of quinine extracted from the bark of the Cin-
chona tree. Nalidixic acid was named Negram, because its activity
was limited to Gram-negative bacteria. It had high plasma protein
binding and was used in simple urinary tract infections. ThePlease cite this article in press as: P. Fernandes, E. Martens, Antibiotics in late cli
j.bcp.2016.09.025pharmacokinetics and spectrum of activity were improved by the
addition of a fluorine in mefloquine and later by the additional aryl
rings to make ciprofloxacin followed by levofloxacin, moxifloxacin,
and a host of other fluoroquinolones with potent broad-spectrum
activity [39]. Resistance to ciprofloxacin and levofloxacin are now
a concern and newer fluoroquinolones that inhibit bacterial DNA
gyrase and topoisomerase IV (gyrA and parC) have been developed.
Delafloxacin (Melinta Therapeutics Inc.) (12), also known as Bax-
dela, was initially synthesized at Abbott Laboratories. Delafloxacin
has potent coverage of key ABSSSI bacterial pathogens, including
MRSA, and is formulated for intravenous and oral administration.
It has completed two Phase 3 trials (known as PROCEED), in which
the active comparator was vancomycin + aztreonam. The first trial
was IV only (NCT01811732) while the second ABSSSI trial was IV/
oral (NCT01984684). Both trials met the primary endpoints
demonstrating delafloxacin was non-inferior to the comparator.
Diarrhea and nausea were the most frequent treatment-related
adverse events reported. Melinta has also initiated a Phase 3 pro-
gram in hospital-treated CABP (NCT02679573), and plans to
develop additional indications such as treatment of cUTI.
Anotherfluoroquinolone inPhase3 clinical development is Zabo-
floxacin (13) (Dong Wha Pharmaceutical Co. Ltd.) Like delafloxacin,
it is a potent inhibitor of the essential bacterial DNA gyrase and
topoisomerase IV. It is highly active against respiratory tract patho-
gens (S. pneumoniae, S. aureus, Streptococcus pyogenes, andMoraxella
catarrhalis) and is being developed in both intravenous and oral for-
mulations to treat CABP. Finafloxacin (MerLion Pharmaceuticals Pte
Ltd.) is another fluoroquinolone that is currently in development. It
is approved in the US for treatment of acute otitis externa (swim-
mer’s ear) caused by P. aeruginosa and S. aureus. It is being developed
for cUTI, acute pyelonephritis, cIAI, ABSSSI, diabetic foot infection,
and tuberculosis. Other potential applications of finafloxacin are
treatment of infections in chronic obstructive pulmonary disease
(COPD) patients and Helicobacter pylori-related gastritis.
Nemonoxacin (TaiGen Biotechnology Co. Ltd.) is a non-
fluorinated quinolone (14) that is being developed as once-a-day
dosing in both oral and intravenous formulations. It has a broad-
spectrum of activity against Gram-positive, Gram-negative, anaero-
bic, and atypical pathogens and is also active against drug-resistant
pathogens, such asMRSA and quinolone-resistantMRSA. Unlike the
fluoroquinolones, it has reduced propensity for resistance develop-
ment, requiring mutations in three different bacterial genes. It has
completed Phase 2 clinical trials for treating CABP and diabetic foot
infections (NCT01944774, NCT00685698).
The fluoroquinolones were discussed at an Advisory committee
meeting convened by the US FDA in November 2015 when a num-
ber of serious side effects such as tendonitis, including Achilles ten-
don rupture, peripheral neuritis and C. difficile colitis were
discussed. These adverse events led to changes, including black
box warnings, which were made to the labeled indications for
the approved fluoroquinolones including ciprofloxacin, levofloxa-
cin and moxifloxacin. The impact of label changes for the older flu-
oroquinolones on new antibacterials in this class will not be known
until their regulatory approval.
DNA gyrase is a proven, selective target for antibacterial product
development as shownby the fluoroquinolones. Coumermycin is an
old natural product antibiotic that inhibits the B subunit of DNA gyr-
ase unlike the fluoroquinolones, that inhibit the A subunit of DNA
gyrase. It is active against Gram-positive bacteria but had unaccept-
able toxicities and is therefore not used clinically. The B subunit of
DNA gyrase has also been the target of more recent drug discovery
efforts [40]. Gepotidacin (GSK2140944; GlaxoSmithKline plc.) (15)
is a triazaacenaphthylene DNA gyrase B subunit inhibitor that inhi-
bits bacterial DNA replication [41]. It is being developed for the
treatment of cUTI, uncomplicated urogenital gonorrhea, and CABP.
Zoliflodacin (ETX0914/AZD0914; Entasis/Astra Zeneca plc.) (16) isnical development, Biochem. Pharmacol. (2016), http://dx.doi.org/10.1016/
Fig. 4. Chemical structures of the following molecules are shown: 11) Solithromycin; 12) Delafloxacin; 13) Zabofloxacin; 14) Nemonoxacin; 15) Gepotidacin; 16) Zoliflodacin.
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is being tested in a Phase 2, randomized, open-label study in gonor-
rhea [43] (NCT02257918) (Fig. 4).11. New oxazolidinones
The oxazolidinones, unlike the previous classes, have no origin
in natural products. This class was first discovered at DuPont but
because of unacceptable toxicities, was not further developed.
The first approved member of this class is linezolid, which was
made at Pharmacia and later marketed by Pfizer after its acquisi-
tion of Pharmacia. It is a bacterial protein synthesis inhibitor
through its binding to the peptidyl transferase site. The peptidyl
transferase site in bacteria is similar to the peptidyl transferase site
in mitochondrial RNA and some of the limitations of dosing with
linezolid, such as myelosuppression, could be related to the effect
on mitochondrial protein synthesis. Linezolid is also a monoamine
oxidase inhibitor and should not be used with serotonergic drugs.
Tedizolid is a newer oxazolidinone, which is more potent and is
effective at a lower dose than linezolid. It has additional binding
sites at the peptidyl transferase site and thus can overcome line-
zolid resistance.
Cadazolid (Actelion Pharmaceuticals Ltd.), a quinolonyl-
oxazolidinone (17) is in Phase 3 development for the treatmentPlease cite this article in press as: P. Fernandes, E. Martens, Antibiotics in late cli
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(IMPACT) are enrolling, and will compare the efficacy and safety
of cadazolid versus vancomycin (NCT01987895, NCT01983683).
MRX-1 (MicuRx Pharmaceuticals Inc.), another novel oxazolidi-
none, is active against multi-drug resistant (MDR) Gram-positive
pathogens, including methicillin-resistant S. aureus (MRSA) and
vancomycin-resistant enterococci (VRE). It is being developed for
the treatment of ABSSSI. It had comparable activity to linezolid
in a Phase 2 ABSSSI trial conducted in China. A second Phase 2
study evaluating patients with ABSSSI is being conducted in the
U.S. (NCT02269319). In these clinical trials, MRX-I has not caused
myelosuppression, the key limiting side effect seen with linezolid.
Sutezolid (PNU-100480) (Sequella, Inc.) is an oxazolidinone
active against multi-drug resistant (MDR) Gram-positive patho-
gens and is being developed for the treatment of extensively
drug-resistant tuberculosis. The drug was initially developed by
Pfizer and successfully completed a Phase 2 study in tuberculosis
(NCT01225640), but was then licensed by Sequella, Inc. in 2013.12. New fatty acid biosynthesis inhibitors
Enzymes involved in fatty acid synthesis have been targets of
antibiotic drug discovery. Triclosan is a chlorinated aromatic com-
pound that is used in soaps and is a known FabI inhibitor (fattynical development, Biochem. Pharmacol. (2016), http://dx.doi.org/10.1016/
Fig. 5. Chemical structures of the following molecules are shown: 17) Cadazolid;
18) Debio 1452; 19) CG400549; 20) Iclaprim.
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thesis being Enoyl-acyl carrier protein reductase). Its use in soaps
was shown to be problematic due to the fact that it induces resis-
tance to other antibiotics by activating efflux pumps [45]. Debio
1452 (Debiopharm Group) (18), which was licensed from Affinium
and is active against all staphylococcal-resistant strains tested to
date, is currently in Phase 2 development. This FabI inhibitor is a
staphylococcus-specific antibiotic designed from the crystal struc-
ture of the active site of the enzyme [46]. It is being developed for
treatment of ABSSSI and osteomyelitis. A Phase 2 study in ABSSSI
(NCT02426918) was initiated in 2015 to compare efficacy of intra-
venous Debio 1450, a Debio 1452 prodrug, with a switch to oral
Debio 1450 compared to intravenous vancomycin with a switch
to oral linezolid. CG400549 (CrystalGenomics Inc.) is another FabI
inhibitor (19) that is being developed [47]. As with the Debio FabI
inhibitors, CG400549 is also a staphylococcus-specific antibiotic,
which is currently in a Phase 2a study in the U.S for the treatment
of ABSSSI caused by MRSA (NCT01593761).
13. New folate biosynthesis inhibitors
Trimethoprim binds to dihydrofolate reductase and inhibits the
reduction of dihydrofolic acid (DHF) to tetrahydrofolic acid (THF)Please cite this article in press as: P. Fernandes, E. Martens, Antibiotics in late cli
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tion with sulfamethoxazole, which inhibits dihydropteroate syn-
thase, an enzyme involved further upstream in the same
pathway. Sulfa drugs have been known even before the discovery
of penicillin. Serious adverse events including photosensitivity
and severe skin rash have been observed with these drugs. Theo-
retically, inhibition of two enzymes in the same pathway is
expected to show synergism and also decrease resistance develop-
ment. Therefore, the combination of trimethoprim with sul-
famethoxazole was developed and is commonly used to treat
urinary tract and skin infections. Trimethoprim is also known to
cause thrombocytopenia by lowering folic acid levels. In the
1990s, pharmaceutical companies like Roche, were looking for
ways to eliminate the use of sulfa drugs in combination with
trimethoprim while improving potency for the oral treatment of
resistant bacterial infections such as MRSA.
Iclaprim (Motif Bio, plc.) is a diaminopyrimidine (20) and a
next-generation dihydrofolate reductase (DHFR) inhibitor that
was first developed by Roche and licensed by Arpida. It is being
developed to treat ABSSSI and HAP [48] and is now in Phase 3
development (NCT02600611, NCT02607618). It exhibits potent,
bactericidal activity against staphylococci, including MSSA and
MRSA and has a low propensity for the development of resistance
(Fig. 5).14. Defensin-mimetic peptides
Antibacterial peptides are innate antibacterial compounds
found in human and animal tissues and cells, especially white cells.
These peptides help in defending the body against bacterial infec-
tions. The first molecule that entered clinical development was
magainin, which was derived from frog skin. However, this mole-
cule dropped out of development due to manufacturing, stability,
and potency issues. Many antibacterial peptides have been
described since the discovery of the magainin peptide. Brilacidin
(Cellceutix Corp/Polymedix/U.Penn) is a defensin-mimetic, non-
peptidic molecule that was designed by chemists to mimic the
amphiphilic properties of antimicrobial peptides and is being
developed to treat ABSSSI. Brilacidin is bactericidal for Gram-
positive and Gram-negative bacteria and is extraordinary in that
it is also bactericidal even for non-replicating bacteria [49]. It tar-
gets the bacterial cell membrane and has been demonstrated to
have low mammalian membrane disruptive properties along with
low mammalian cell cytotoxicity. Two Phase 2 studies
(NCT02052388) were completed successfully in 430 subjects with
ABSSSI comparing three dosing regimens of brilacidin to dapto-
mycin for the treatment of ABSSSI. All brilacidin treatment regi-
mens were shown to be well tolerated.15. Other classes
Ridinilazole (SMT19969) (Summit Therapeutics) is a selective,
non-absorbable novel compound for the treatment of C. difficile
infection with reduced disease recurrence [50]. It is active against
all strains of C. difficile and was shown to be superior to van-
comycin in a Phase 2 study (NCT02092935).16. Old antibiotics with new dosing regimens
16.1. Ramoplanin
Ramoplanin (NTI-851) (Nanotherapeutics Inc.) is an old glycol-
ipodepsipeptide that inhibits cell wall biosynthesis and has a bac-
tericidal effect. It is not absorbed orally and is proposed to enter anical development, Biochem. Pharmacol. (2016), http://dx.doi.org/10.1016/
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but no clinical trial is currently underway in the U.S.
16.2. Fusidane
Fusidic acid is a steroidal natural product belonging to the fusi-
dane class of antibiotics that was discovered in the 1960s at Leo
Laboratories. Fusidic acid is a protein synthesis inhibitor, and the
only bacterial elongation factor inhibitor that has been developed
for clinical use. Oral fusidic acid has a long history of safety and
efficacy outside the U.S. against ABSSSI, including MRSA, and bone
and joint infections. However, it was never granted regulatory
approval in the United States. Cempra has a patented oral loading
dose regimen of fusidic acid (sodium fusidate) to minimize devel-
opment of bacterial resistance. This loading dose/maintenance
dose regimen was tested in a Phase 2 ABSSSI trial against linezolid
as a comparator (NCT00948142). It is now being tested in pivotal
Phase 3 trials for treatment of ABSSSI as well as an exploratory trial
for long-term oral treatment of refractory bone and joint infections
[51] (NCT02570490, NCT02569541). There is no FDA guidance or
approved treatment for the latter indication.
16.3. Fosfomycin
Fosfomycin (also called phosphonomycin) was originally iso-
lated from a Streptomyces sp. but is now made synthetically. It
has a broad-spectrum of activity and is bactericidal. It inhibits
UDP-N-acetylglucosamine-3-enolpyruvyltransferase, also known
as MurA, an enzyme that catalyzes the first committed step in cell
wall biosynthesis. Fosfomycin is a phosphoenolpyruvate phos-
phate (PEP) analog that inhibits MurA by alkylating an active site
cysteine residue in the enzyme. Fosfomycin enters the bacterial
cell through the glycerophosphate transporter. Fosfomycin is avail-
able for oral use but not intravenous use in the US. However, it is
available for intravenous use overseas [52]. It has good activity
against CRE pathogens and a new intravenous dosing formulation
(Zavante Therapeutics) is currently under development. A Phase
3 comparative trial has been initiated to evaluate intravenous fos-
fomycin (also known as ZTI-01) against piperacillin/tazobactam in
the treatment of cUTI and acute pyelonephritis in hospitalized
adults (NCT02753946).17. Summary
The above sections summarize those antibiotics that are in late
clinical development. The discussion of early-stage molecules, such
as POL7080 (Polyphor Ltd.), a macrocycle protein epitope mimetic
[53], teixobactin, a novel, cyclic depsipeptide, which inhibits cell
wall synthesis by binding to lipid II and lipid III (isolated from
Eleftheria terrae, a Gram-negative bacterium that had previously
been uncultured) [54] and lugdunin, a novel thiazolidine-
containing cyclic peptide (produced by Staphylococcus lugdunensis)
[55] that inhibits Gram-positive bacteria, are beyond the scope of
this review. Early-stage molecules have significantly higher risk
of failure and those that inhibit unproven targets and unproven
chemical classes have an even greater risk than known classes.
Despite the higher risk, the search must go on, and drug develop-
ers, government organizations and investors must take calculated
risks with new approaches in order to avoid returning to the pre-
penicillin era.
Most of the new antibiotics in late-stage development belong to
existing classes of antibiotics. So is there ‘‘nothing new under the
sun” (Ecclesiastes 1:9)? New approaches that address drug resis-
tant pathogens could save lives but it is not correct that there is
lower risk for drug resistance with novel targets and novel classesPlease cite this article in press as: P. Fernandes, E. Martens, Antibiotics in late cli
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line [5]. Analogs of existing classes are equally difficult to develop
as novel compounds against novel targets, since every chemical
change in old classes of molecules do pose safety and efficacy risks.
Just as new patents recognize novel molecules, new antibiotics,
even those that belong to old classes, deserve the acknowledgment
that they are also difficult to develop and are also creative since
many of these classes have been mined for decades. Most of the
new antibiotics in late-stage development originated from natural
products. The lesson learned is that complex molecules with mul-
tiple sites of interaction are a higher hurdle for mutations and
resistance selection among bacteria.18. Conclusion
Even the limited investments that are being made today are
mostly made to develop intravenous antibiotics for use in hospi-
tals. This choice has been primarily driven by less price sensitivity
for hospital drugs, which is equated to higher revenue. With rising
outpatient antibiotic resistance in respiratory and urinary tract
infections, new oral antibiotics for outpatient use are urgently
needed [17,56]. Solithromycin and omadacycline are two antibi-
otics being developed for both outpatient and hospital use.
Another important point is that most antibiotics are developed
for adults with the expectation that they will be used ‘‘off-label”
in children. New legislation has required the development of new
antibiotics for use in children. Since most new antibiotics only
have intravenous formulations, new antibiotics for pediatric use
will only be used in hospitalized children. Some antibiotic classes,
such as the tetracyclines and fluoroquinolones, have unacceptable
side effects in children and are therefore not approved for use in
this special patient population. This leaves only a few classes of
antibiotics for development for oral administration in pediatrics.
The macrolide antibiotic class has been preferred for use in chil-
dren. Solithromycin, the new fluoroketolide, belongs to the macro-
lide class and is being developed for both outpatient and inpatient
pediatric use. As in the case of drug development exclusively for
pediatric use, very few drugs are developed for infections that
occur during pregnancy. Safety issues are believed to be a high hur-
dle in this special population. Development of solithromycin is
expected to be pursued to treat infections in pregnancy and has
shown desirable antibacterial activities and safety in pre-clinical
studies. Notably, addressing all populations will become key as
resistance rates rise.
Development of new antibiotics requires large investments. It is
not feasible to obtain the approximately $200MM in investments to
perform the required nonclinical work, clinical trials and manufac-
ture of the product if an antibiotic is left on the shelf for use only in
times of future need. Just as governments invest in ammunition to
protect our countries, governments will also need to make invest-
ments to create new antibiotics to add to our armamentarium.
Stockpiling these antibiotics will also be necessary to ensure that
they are available in the event of immediate need, such as during
bioterrorism events. There have been several models recently pro-
posed to increase the incentives for developing new antibiotics in
order to combat the growing problem of antimicrobial resistance.
The first involves the concept of antibiotic reimbursement that is
delinked from sales [57]. Specifically, this would mean that the link
between rewards for R&D (and innovation) and revenues of sales
(price and volume) would be broken [58]. In other words, the
innovation could be rewarded through prizes and/or fixed series
of milestone payments, thereby encouraging companies to develop
new antibiotics [57]. A second approach for creating incentives for
new antibiotics is the Options Market for Antibiotics (OMA) model
[59]. This model would incentivize early development yet alsonical development, Biochem. Pharmacol. (2016), http://dx.doi.org/10.1016/
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model further emphasizes that companieswould be given subsidies
at different stages in the drug’s life cycle as opposed to only at the
time of marketing. The hope would be to stimulate the R&D of new
antibiotics by pharmaceutical companies due to the fact that cur-
rent polices have been largely inadequate. The arms race is, andwill
always be, an on-going battle with bacteria that are continuously
evolving due to selective pressure to develop resistance to the
antibiotic du jour. We can only hope to stay ahead with our pursuit
of new antibiotics.
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